ALCAM, Activated Leukocyte Cell Adhesion Molecule, in Clinical Gastric Cancer and Patient’s Response to Chemotherapies

Yang, Yi Ming, Ruge, Fiona, Ji, Ke, Jia, Shuqin, Jia, Yongning, Sanders, Andrew J ORCID: 0000-0002-7997-5286, Ji, Jiafu and Jiang, Wen G (2023) ALCAM, Activated Leukocyte Cell Adhesion Molecule, in Clinical Gastric Cancer and Patient’s Response to Chemotherapies. Anticancer Research, 43 (4). pp. 1463-1475. doi:10.21873/anticanres.16295

Preview

Text (Peer reviewed version) 12547 Yang et al (2023) ALCAM, Activated Leukocyte Cell Adhesion.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (2MB) | Preview

Abstract

Background/aim: Activated leukocyte cell adhesion molecule (ALCAM/CD166), a member of the immunoglobulin superfamily, has been shown to regulate cell adhesion through both homotypic and heterotypic interactions. In cancer, it might be involved in disease progression and chemotherapy drug resistance. The present study explored the clinical and prognostic significance of ALCAM in gastric cancer and its impact on patient's responses to neoadjuvant chemotherapies and cancer cells' response to chemodrugs in vitro. Materials and methods: Two independent cohorts were included to evaluate the link between ALCAM and the clinical outcomes and pathological factors of the patients. The gastric cancer cell lines HGC27 and AGS were used to generate ALCAM knockdown cell models. The cytotoxicity of chemotherapy drugs was examined using ALCAM knockdown cell models. Results: Patients with gastric cancer who had high levels of ALCAM transcripts showed a significantly shorter overall survival in both cohorts (p=0.043 and 0.006, respectively). Patients who resisted to neoadjuvant chemotherapy had marginally higher levels of ALCAM than those responded (p=0.056). Patients with low levels of ALCAM expression and resisted to neoadjuvant chemotherapy had the worst clinical outcome with a significantly shorter overall survival (p=0.004) and disease-free survival (p=0.006), whereas such results did not appear in high ALCAM expression patients. ALCAM knockdown cells were more sensitive to Cisplatin, Oxaliplatin and 5-Fluorouracil compared with their respective control cells. Conclusion: ALCAM acts as a negative prognostic indicator in patients with gastric cancer and high levels of ALCAM expression result in increased chemotherapy drug resistance. Keywords: ALCAM; CD166; drug resistance; gastric cancer; gastric cell model; neoadjuvant chemotherapy; survival.

Item Type:	Article
Article Type:	Article
Uncontrolled Keywords:	Activated-Leukocyte Cell Adhesion Molecule; Stomach Neoplasms; ALCAM; CD166; Drug resistance; Gastric cancer; Gastric cell model; Neoadjuvant chemotherapy; Survival
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Schools and Research Institutes > School of Education and Science
Research Priority Areas:	Place, Environment and Community
Depositing User:	Susan Turner
Date Deposited:	29 Mar 2023 13:45
Last Modified:	21 Jun 2024 13:15
URI:	https://eprints.glos.ac.uk/id/eprint/12547

University Staff: Request a correction | Repository Editors: Update this record